Analysis of P450CYP2C9 polymorphisms in Italian patients with low warfarin dose requirement.

被引：0
|
作者：
Patrosso, CM [1 ]
Lando, G [1 ]
Figini, A [1 ]
Mostarda, G [1 ]
Caimi, M [1 ]
Baudo, F [1 ]
Marocchi, A [1 ]
机构：
[1] Niguarda Ca Granada Hosp, Milan, Italy
来源：
CLINICAL CHEMISTRY | 2000年 / 46卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
515
引用
收藏
页码：A134 / A134
页数：1
相关论文
共 50 条
  • [21] The risk of overanticoagulation in patients with cytochrome P450CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
    Visser, LE
    van Vliet, M
    van Schaik, RHN
    Kasbergen, AAH
    De Smet, PAGM
    Vulto, AG
    Hofman, A
    Van Duijn, CM
    Stricker, BHC
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (03) : 369 - 369
  • [22] Analysis of CYP2C9 polymorphisms (*2 and*3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR
    Yasmeen, Faiza
    Ghafoor, Muhammad Bilal
    Khalid, Abdul Wadood
    Latif, Waqas
    Mohsin, Shahida
    Khaliq, Shagufta
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 40 (02) : 218 - 224
  • [23] Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR
    Faiza Yasmeen
    Muhammad Bilal Ghafoor
    Abdul Wadood Khalid
    Waqas Latif
    Shahida Mohsin
    Shagufta Khaliq
    Journal of Thrombosis and Thrombolysis, 2015, 40 : 218 - 224
  • [24] The risk of bleeding complications in patients with cytochrome P450CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
    Visser, LE
    van Schaik, RHN
    van Vliet, M
    Trienekens, PH
    De Smet, PAGM
    Vulto, AG
    Hofman, A
    van Duijn, CM
    Stricker, BHC
    THROMBOSIS AND HAEMOSTASIS, 2004, 92 (01) : 61 - 66
  • [25] Influence of cytochrome P450CYP2C9 genotypes in lung cancer risk
    García-Martín, E
    Martínez, C
    Ladero, JM
    Gamito, FJG
    Rodriguez-Lescure, A
    Agúndez, JAG
    CANCER LETTERS, 2002, 180 (01) : 41 - 46
  • [26] Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population
    Chowdhury, Zahid Sadek
    Shahjin, Farah
    Akter, Farhana
    Ahmed, Maizbha Uddin
    Islam, Mohammad Safiqul
    Bin Sayeed, Muhammad Shandaat
    Islam, Reazul
    Hasnat, Abul
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 30 (02) : 341 - 346
  • [27] CYP2C9 gene polymorphisms and warfarin dose requirement: a single-center experience in Turkey
    Yildirim, Rahsan
    Gundogdu, Mehmet
    Kurnaz, Fatih
    Yildirim, Abdulkadir
    Aksoy, Hulya
    Erdem, Fuat
    Kiki, Ilhami
    Akbas, Emin Murat
    Cerrah, Serkan
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2012, 42 (06) : 981 - 986
  • [28] Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype
    Kwon, Min-Jung
    On, Young-Keun
    Huh, Wooseong
    Ko, Jae-Wook
    Kim, Duk-Kyung
    Kim, June Soo
    Lee, Soo-Youn
    CLINICA CHIMICA ACTA, 2011, 412 (23-24) : 2343 - 2345
  • [29] Early overanticoagulation with acenocournarol due to a genetic polymorphism of cytochrorne P450CYP2C9
    André-Kerneïs, E
    Leroy-Matheron, C
    Gouault-Heilmann, M
    BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (08) : 761 - 764
  • [30] Endstage renal disease (ESRD) reduces hepatic cytochrome P450CYP2C9 (CYP2C9) activity.
    Dreisbach, AW
    Japa, S
    Kamath, BL
    Mowry, SE
    Gebrekal, AB
    Lertora, JJL
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 716A - 716A
12345